Recent studies have confirmed that the efficacy of PARP inhibitors is improved not only in ovarian cancers displaying germline or somatic BRCA mutations but also in cancers in which HRD is caused by other underlying etiologies. This evidence concerns the gene PARP1 and ovarian carcinoma.